Non-vitamin K antagonist oral anticoagulant use at doses inappropriately lower than recommended in outpatient older adults: a real-life data

被引:2
|
作者
Erdogan, Tugba [1 ]
Erdogan, Onur [2 ]
Ozturk, Savas [3 ]
Oren, Meryem Merve [4 ]
Karan, Mehmet Akif [1 ]
Bahat, Gulistan [1 ]
机构
[1] Istanbul Univ, Istanbul Med Sch, Dept Internal Med, Div Geriatr, Istanbul, Turkey
[2] Istinye State Hosp, Dept Cardiol, Istanbul, Turkey
[3] Haseki Training & Res Hosp, Dept Nephrol, Istanbul, Turkey
[4] Istanbul Univ, Istanbul Med Sch, Dept Publ Hlth, Istanbul, Turkey
关键词
Atrial fibrillation; Inappropriate drug use; Low dose; Non-vitamin K antagonist oral anticoagulants;
D O I
10.1007/s41999-021-00452-0
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Background/Purpose There has been a rapid increase in the use of non-vitamin K-antagonist oral anticoagulants (NOAC). Current guidelines recommend dose adjustments be made in accordance with certain criteria for each NOAC. This study is aimed at determining whether or not NOAC were prescribed for non-valvular atrial fibrillation (AF) in guideline-recommended doses in community-dwelling older adults. Methods Older adults taking NOAC for non-valvular AF presenting to a cardiology outpatient clinic for the first time were included in the study. The NOAC dose for each patient was assessed based on the recommendations of the European Society of Cardiology and were categorized as appropriate or inappropriate (low or high dose). The patients were also evaluated for demographic data, diseases, CHA2DS2-VASc score, HASBLED score, frailty and falls in the previous year. Results A total of 302 older adults were included in the study, with a mean age of 75.5 +/- 7.5 years. One hundred eighty-four patients (60.9%) were found to be on appropriate doses of NOAC, while 109 (36.1%) were on inappropriately low doses and nine (2.98%) were on inappropriately high doses. Accordingly, 39.1% of the AF patients were found to be on inappropriate doses of NOAC, 92.4% of which were inappropriately low. A multivariate logistic regression analysis revealed that the only factor associated with inappropriate low-dose NOAC use was patient age (OR = 1.061, 95% CI = 1.009-1.116, p = 0.022). Conclusion Our study suggests that the inappropriate use of lower dose NOAC may emerge as a significant problem in outpatient older adults. This inappropriate practice seems to be associated with older age rather than the diseases, CHA2DS2-VASc/HASBLED scores, frailty and presence of falls.
引用
收藏
页码:809 / 816
页数:8
相关论文
共 24 条
  • [1] Non-vitamin K antagonist oral anticoagulant use at doses inappropriately lower than recommended in outpatient older adults: a real-life data
    Tugba Erdogan
    Onur Erdogan
    Savas Ozturk
    Meryem Merve Oren
    Mehmet Akif Karan
    Gulistan Bahat
    European Geriatric Medicine, 2021, 12 : 809 - 816
  • [2] Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life
    Giustozzi, Michela
    Vedovati, Maria Cristina
    Verdecchia, Paolo
    Pierpaoli, Lucia
    Verso, Melina
    Conti, Serenella
    Cianella, Federica
    Marchesini, Emanuela
    Filippucci, Esmeralda
    Agnelli, Giancarlo
    Becattini, Cecilia
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2016, 33 : 42 - 46
  • [3] Current clinician perspective on non-vitamin K antagonist oral anticoagulant use in challenging clinical cases
    Turk, Ugur Onsel
    Acar, Rezzan Deniz
    Akgun, Taylan
    Emren, Volkan
    Kanat, Selcuk
    Karacaglar, Emir
    Kepez, Alper
    Kul, Seref
    Ozel, Erdem
    Simsek, Evrim
    Tuluce, Selcen Yakar
    Tuluce, Kamil
    Camm, A. John
    TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, 2020, 48 (03): : 289 - 303
  • [4] Real-world Data and Recommended Dosage of Non-vitamin K Oral Anticoagulants for Korean Patients
    Joung, Boyoung
    KOREAN CIRCULATION JOURNAL, 2017, 47 (06) : 833 - 841
  • [5] Real-life experience with non-vitamin K antagonist oral anticoagulants versus warfarin in patients undergoing elective cardioversion of atrial fibrillation
    Itainen-Stromberg, Saga
    Hekkala, Anna-Mari
    Aro, Aapo L.
    Vasankari, Tuija
    Airaksinen, Kari Eino Juhani
    Lehto, Mika
    ANNALS OF NONINVASIVE ELECTROCARDIOLOGY, 2020, 25 (05)
  • [6] Practice-derived data on non-vitamin K antagonist oral anticoagulant therapy to complement observations from randomized trials
    Domek, Magdalena
    Gumprecht, Jakub
    Ding, Wern Yew
    Lip, Gregory Y. H.
    Lane, Deirdre A.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2020, 22 (0I) : I1 - I12
  • [7] What do the guidelines suggest for non-vitamin K antagonist oral anticoagulant use for stroke prevention in atrial fibrillation?
    Shahid, Farhan
    Shantsila, Eduard
    Lip, Gregory Y. H.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2016, 18 (0I) : 18 - 24
  • [8] A meta-summary of case reports of non-vitamin K antagonist oral anticoagulant use in patients with left ventricular thrombus
    Leow, Aloysius Sheng-Ting
    Sia, Ching-Hui
    Tan, Benjamin Yong-Qiang
    Loh, Joshua Ping-Yun
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2018, 46 (01) : 68 - 73
  • [9] Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial
    Joosten, Linda P. T.
    van Doorn, Sander
    van de Ven, Peter M.
    Kohlen, Bart T. G.
    Nierman, Melchior C.
    Koek, Huiberdina L.
    Hemels, Martin E. W.
    Huisman, Menno V.
    Kruip, Marieke
    Faber, Laura M.
    Wiersma, Nynke M.
    Buding, Wim F.
    Fijnheer, Rob
    Adriaansen, Henk J.
    Roes, Kit C.
    Hoes, Arno W.
    Rutten, Frans H.
    Geersing, Geert-Jan
    CIRCULATION, 2024, 149 (04) : 279 - 289
  • [10] 'Real world' use of non-vitamin K antagonist oral anticoagulants (NOACs): Lessons from the Dresden NOAC Registry
    Eikelboom, John W.
    Weitz, Jeffrey I.
    THROMBOSIS AND HAEMOSTASIS, 2015, 113 (06) : 1159 - 1161